IP Library Granted Patent US 10,117,934
Granted Patent B2
US 10,117,934 · App. 14/995,842 · Granted Nov 6, 2018

Conjugated lipomers and uses thereof

Inventors: James E. Dahlman (Cambridge, MA); Avraham D. Schroeder (Newton, MA); Daniel Griffith Anderson (Framingham, MA); Robert S. Langer (Newton, MA); Christopher G. Levins (Flemington, NJ)
Assignee: Massachusetts Institute of Technology
A61K47/22A61K9/0019A61K9/1272A61K47/34A61K47/543A61K47/59A61K47/6907A61K47/6911A61K47/6921C07D257/02C07D273/00C07D273/08C07D295/084C08G73/10C12N15/1137C12N15/1138C12N2310/14C12N2320/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,117,934
App. No.
14/995,842
Granted
Nov 6, 2018
Kind
B2
Abstract

The present invention provides inventive conjugated polyethyleneimine (PEI) polymers and conjugated aza-macrocycles (collectively referred to herein as “conjugated lipomers” or “lipomers”) containing one or more groups of the formula (iii): wherein R 3 and R 4 are as defined herein. Also provided are compositions comprising the inventive conjugated lipomers, and methods of preparation and use.

Claims (31)

1. A conjugated lipomer of Formula (IV):

or salt thereof; wherein:

each instance of L 3 is independently:

each instance of R 8 is independently hydrogen; acyl; silyl; sulfonyl; an amino protecting group; substituted or unsubstituted alkyl; substituted or unsubstituted alkenyl; substituted or unsubstituted alkynyl; substituted or unsubstituted heteroalkyl; substituted or unsubstituted heteroalkenyl; substituted or unsubstituted heteroalkynyl; substituted or unsubstituted carbocyclyl; substituted or unsubstituted heterocyclyl; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; or

provided the conjugated lipomer contains two, three, or four groups of Formula (iii′);

each instance of R 3 is independently substituted or unsubstituted C 5-20 alkyl; substituted or unsubstituted alkenyl; substituted or unsubstituted alkynyl; substituted or unsubstituted heteroalkenyl; substituted or unsubstituted heteroalkynyl; substituted or unsubstituted carbocyclyl; substituted or unsubstituted heterocyclyl; substituted or unsubstituted heteroaryl; or a hydrophilic polymer;

each instance of R 4 is independently hydrogen, acyl; silyl; a hydroxyl protecting group; substituted or unsubstituted alkyl; substituted or unsubstituted alkenyl; substituted or unsubstituted alkynyl; substituted or unsubstituted heteroalkyl; substituted or unsubstituted heteroalkenyl; substituted or unsubstituted heteroalkynyl; substituted or unsubstituted carbocyclyl; substituted or unsubstituted heterocyclyl; substituted or unsubstituted aryl; or substituted or unsubstituted heteroaryl;

each instance of m and p is 1;

q is 2; and

the dashed curved line, together with G and Y, is a covalent bond.

2. The conjugated lipomer of claim 1 , wherein each instance of R 8 is independently hydrogen or a group of Formula (iii′).

3. The conjugated lipomer of claim 1 , wherein each instance of R 3 is independently substituted or unsubstituted C 5-20 alkyl or a hydrophilic polymer.

4. The conjugated lipomer of claim 1 , wherein at least one instance of R 3 is substituted or unsubstituted C 5-20 alkyl.

5. The conjugated lipomer of claim 1 , wherein the lipomer is of Formula (V):

or salt thereof.

6. The conjugated lipomer of claim 1 , wherein the conjugated lipomer is selected from the group consisting of:

and salts thereof.

7. A composition comprising one or more conjugated lipomers of claim 1 , and, optionally, an excipient.

8. The composition of claim 7 , wherein the composition is a pharmaceutical composition or a cosmetic composition.

9. The composition of claim 7 , wherein the composition further comprises an agent.

10. The composition of claim 9 , wherein the agent is an organic molecule, inorganic molecule, protein, peptide, polynucleotide, targeting agent, isotopically labeled chemical compound, vaccine, or immunological agent.

11. The composition of claim 10 , wherein the agent is a polynucleotide.

12. The composition of claim 7 , wherein the one or more conjugated lipomers are in the form of a particle.

13. The composition of claim 9 , wherein the agent is a polynucleotide that encodes a protein or peptide.

14. The composition of claim 11 , wherein the polynucleotide is DNA.

15. The composition of claim 11 , wherein the polynucleotide is RNA.

16. The composition of claim 15 , wherein the RNA is RNAi, dsRNA, siRNA, shRNA, miRNA, or antisense RNA.

17. A method of preparing a conjugated lipomer of claim 1 , the method comprising contacting a compound of Formula (III), or salt thereof, with an epoxide of Formula (xii):

wherein each instance of L 2 is independently:

provided that at least one R 8 group is hydrogen;

to provide the conjugated lipomer of claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2016
From: DAHLMAN, JAMES E.; SCHROEDER, AVRAHAM D.; ANDERSON, DANIEL GRIFFITH; LANGER, ROBERT S.; LEVINS, CHRISTOPHER G.
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 037867/0813 →
Continuity (3)
Continuation 13428695 · Mar 23, 2012
Provisional Application 61468455 · Mar 28, 2011
Related Publication 20160206740A1 · Jul 21, 2016
Cited By (2)
US 12,390,528 US 12,648,959